ABVC
ABVC BioPharma, Inc.
There isn't enough reported data to score ABVC yet.
ABVC Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
ABVC's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
ABVC PE Valuation
ABVC has no meaningful PE right now: it lost money over the past year.
ABVC Forward outlook
There aren't enough analyst estimates for ABVC to show an outlook.
ABVC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$1.38 | +$2.02 |
| Q2 2024 | -$2.18 | +$1.50 |
| Q1 2024 | -$2.77 | +$0.83 |
| Q4 2023 | -$2.97 | +$2.03 |
| Q3 2023 | -$3.40 | +$3.35 |
| Q2 2023 | -$3.68 | +$2.67 |
| Q1 2023 | -$3.60 | +$2.95 |
| Q4 2022 | -$5.00 | +$0.05 |
ABVC is still losing money, but far less than before: $0.20 per share over the past year, against $6.75 at its worst in late 2022.
ABVC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $796K | +104% |
| Q4 2024 | $2K | -9.2% |
| Q3 2024 | $389.3K | +2351% |
| Q2 2024 | $117.1K | +1818% |
| Q1 2024 | $1.2K | -99% |
| Q4 2023 | $2.2K | -100% |
| Q3 2023 | $15.9K | -62% |
| Q2 2023 | $6.1K | -98% |
ABVC's revenue is growing: −$795,950 last quarter, down 779% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2025 | -247% | -260 points |
| Q4 2024 | -16997% | +73609 points |
| Q3 2024 | 13% | +13579 points |
| Q2 2024 | -834% | +35078 points |
| Q1 2024 | -285841% | -284355 points |
| Q4 2023 | -90606% | -90074 points |
| Q3 2023 | -13566% | -4775 points |
| Q2 2023 | -35912% | -35257 points |
ABVC's operating margin was −247% last quarter, up 285595 points from the same quarter a year ago, near the top of its range since 2019.
ABVC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$894.2K | -$354.4K |
| Q2 2025 | -$894.2K | +$119.9K |
| Q1 2025 | -$539.8K | -$66.7K |
| Q1 2024 | -$473.2K | +$1M |
| Q1 2023 | -$1.5M | +$1.6M |
| Q2 2022 | -$3.5M | -$2M |
| Q1 2022 | -$3.1M | -$1.7M |
| Q4 2021 | -$1.8M | +$1.4M |
ABVC has burned cash in almost every quarter: −$4M over the past year, against −$3M the year before.
ABVC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.3% | +598K shares |
| 1 year | +15% | +3.4M shares |
| 3 years | +706% | +23.3M shares |
| 5 years | +992% | +24.2M shares |
| Available history | +1423% | +24.9M shares |
ABVC has 27M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q4 2021 | — |
ABVC Net Leverage
ABVC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ABVC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.8 | Neutral |
| Stochastic | 51.7 | Neutral |
ABVC's weekly RSI is 43 (neutral) and its Stochastic is 52 (neutral).
ABVC PE vs Healthcare Sector
ABVC has no meaningful PE right now: it lost money over the past year.
ABVC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.00 | 4% below |
| 20 week MA | $1.07 | 10% below |
| 50 week MA | $1.36 | 29% below |
| 100 week MA | $1.60 | 40% below |
| 200 week MA | $2.06 | 53% below |
ABVC is in a downtrend: it's below all five of its weekly moving averages, and 53% below its 200-week average.
ABVC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.5 | $52.0 | +1% |
| 2021 | $52.0 | $37.7 | -27% |
| 2022 | $37.7 | $6.90 | -82% |
| 2023 | $6.90 | $1.16 | -83% |
| 2024 | $1.16 | $0.58 | -50% |
| 2025 | $0.58 | $2.43 | +319% |
| 2026 YTD | $2.43 | $0.96 | -60% |
ABVC's yearly returns have swung widely, from +319% in 2025 to −83% in 2023. It's down 60% so far in 2026.